Earnings Releases·Nov 4, 2026, 4:10 PM ET

electroCore — Third Quarter 2026 Earnings Summary

Net sales rose 12% year-over-year to $9.7 million, while GAAP net loss narrowed 61% to $1.3 million and Adjusted EBITDA loss improved 67% to $0.7 million.
Full-year 2026 revenue guidance was revised to $39–$42 million, with preliminary 2027 guidance targeting 30–40% revenue growth and a projected first positive Adjusted EBITDA quarter by end of 2027.
Quell sales surged 102% year-over-year to $1.2 million, driven by a 111% increase in VA Fibromyalgia revenue, while the company transitioned 91% of prescription orders to a new Lovell Government Services distribution agreement.
Cash and marketable securities declined to $7.5 million from $11.6 million at year-end 2025, with management citing risks related to potential funding needs and Nasdaq listing maintenance.